Its a bidding war and ST Engineering upped their bid to $78
as per Bloomberg.
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
as per Bloomberg.
RPM International raised flooring systems manufacturer for $26M
Mar. 29, 2021 5:30 PM ETRPM International Inc. (RPM)
Mar. 29, 2021 5:30 PM ETRPM International Inc. (RPM)
- RPM International (NYSE:RPM) announces that its Fibergrate Composite Structures business has acquired Bison Innovative Products, a leading manufacturer of raised flooring systems.
- It is headquartered in Denver, Colorado, Bison has annual net sales of approximately $26M.
The whole sector is overbought and old news.
It's at $94.79
15% down will paint before 15% up.
Bookmark the post.
I want a bigger office btw.
Gummy of The Day
AMRN
$6.70 on the ask pre-market
no volume yet
DUBLIN, Ireland and BRIDGEWATER, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that following a review and approval recommendation by the European Medicines Agency (EMA), the European Commission (EC) has approved the marketing authorization application for VAZKEPA (icosapent ethyl) to reduce the risk of cardiovascular events in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established cardiovascular disease or diabetes and at least one additional cardiovascular risk factor.
Amarin’s icosapent ethyl was approved for cardiovascular risk reduction by the U.S. Food and Drug Administration (FDA) in December 2019 and is marketed in the U.S. under the brand name, VASCEPA®.
“The approval of VAZKEPA marks a significant milestone for high-risk cardiovascular patients in Europe as it offers the first and only EC-approved therapy to reduce cardiovascular risk in high-risk statin-treated patients who have elevated triglycerides,” said Steven Ketchum, senior vice president, president of R&D and chief scientific officer of Amarin. “We look forward to launching VAZKEPA in Europe as it is an exciting opportunity for Amarin to make a difference in the lives of the many millions of patients throughout Europe who are at risk of a cardiovascular event.”
AMRN
$6.70 on the ask pre-market
no volume yet
DUBLIN, Ireland and BRIDGEWATER, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that following a review and approval recommendation by the European Medicines Agency (EMA), the European Commission (EC) has approved the marketing authorization application for VAZKEPA (icosapent ethyl) to reduce the risk of cardiovascular events in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established cardiovascular disease or diabetes and at least one additional cardiovascular risk factor.
Amarin’s icosapent ethyl was approved for cardiovascular risk reduction by the U.S. Food and Drug Administration (FDA) in December 2019 and is marketed in the U.S. under the brand name, VASCEPA®.
“The approval of VAZKEPA marks a significant milestone for high-risk cardiovascular patients in Europe as it offers the first and only EC-approved therapy to reduce cardiovascular risk in high-risk statin-treated patients who have elevated triglycerides,” said Steven Ketchum, senior vice president, president of R&D and chief scientific officer of Amarin. “We look forward to launching VAZKEPA in Europe as it is an exciting opportunity for Amarin to make a difference in the lives of the many millions of patients throughout Europe who are at risk of a cardiovascular event.”
250K shares traded, its not moving really.
This is an old favorite, I know stoney's played it quite a bit and the chatroom was trading it back when it was in the teens. The drop to $4 hurt a lot of people so I'd imagine there's a lot of positions that are glad to get out on this pop. If it can build a base down here it should run to $7 at some point I would think.
--OraSure submits COVID-19 rapid antigen test for self-testing to FDA 07:09 OSUR
--Enservco initiated with a Buy at Alliance Global Partners 07:06 ENSV Alliance
--Bicycle Therapeutics updates progress 'outside of oncology' 07:06 BCYC Bicycle Therapeutics announced progress updates for its Bicycle-based partnered programs outside of oncology. "Over the last five years, Bicycle's strategy has been to use our novel technology to discover and develop a pipeline of innovative assets in oncology while additionally using non-dilutive funding and collaborations to explore the therapeutic potential of Bicycles in disease areas outside of oncology. Today, for the first time, we are providing an overview on our progress in demonstrating the broad utility of this platform to create molecules with the potential to treat some of the most serious diseases and address future healthcare challenges," said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. "It's incredibly exciting to see how the Company has worked innovatively and highly collaboratively with many diverse institutions to address these challenges and, at the same time, generated significant revenues to offset the costs of developing and progressing our internal oncology pipeline. I would like to thank all of our collaborators for their enthusiasm in this endeavor and look forward to continuing our work to advance these important molecules." Bicycle has achieved the first milestone in its collaboration with Dementia Discovery Fund, DDF, and the University of Oxford's ARUK Oxford Drug Discovery Institute. The Company identified and optimized nM affinity Bicycles to TREM2, a genetically validated target for the treatment of dementia, and nM affinity Bicycles to transferrin receptor 1 (TfR1), a molecular shuttle...Innovate UK's Biomedical Catalyst (BMC) awarded the Company funding to advance a Bicycle inhibitor for a key cell wall biosynthesis target in Enterobacterales, Penicillin Binding Protein 3 (PBP3). Bicycle is using its proprietary platform to try to address the significant healthcare challenge of antimicrobial resistance and has identified several potential Bicycle PBP3 inhibitors.
--Bicycle Therapeutics updates progress 'outside of oncology' 07:06 BCYC Bicycle Therapeutics announced progress updates for its Bicycle-based partnered programs outside of oncology. "Over the last five years, Bicycle's strategy has been to use our novel technology to discover and develop a pipeline of innovative assets in oncology while additionally using non-dilutive funding and collaborations to explore the therapeutic potential of Bicycles in disease areas outside of oncology. Today, for the first time, we are providing an overview on our progress in demonstrating the broad utility of this platform to create molecules with the potential to treat some of the most serious diseases and address future healthcare challenges," said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. "It's incredibly exciting to see how the Company has worked innovatively and highly collaboratively with many diverse institutions to address these challenges and, at the same time, generated significant revenues to offset the costs of developing and progressing our internal oncology pipeline. I would like to thank all of our collaborators for their enthusiasm in this endeavor and look forward to continuing our work to advance these important molecules." Bicycle has achieved the first milestone in its collaboration with Dementia Discovery Fund, DDF, and the University of Oxford's ARUK Oxford Drug Discovery Institute. The Company identified and optimized nM affinity Bicycles to TREM2, a genetically validated target for the treatment of dementia, and nM affinity Bicycles to transferrin receptor 1 (TfR1), a molecular shuttle...Innovate UK's Biomedical Catalyst (BMC) awarded the Company funding to advance a Bicycle inhibitor for a key cell wall biosynthesis target in Enterobacterales, Penicillin Binding Protein 3 (PBP3). Bicycle is using its proprietary platform to try to address the significant healthcare challenge of antimicrobial resistance and has identified several potential Bicycle PBP3 inhibitors.
--Deutsche upgrades 'cleaned up' DXC to Buy with $44 price target 07:04 DXC
--Evolus price target raised to $15 from $9 at Mizuho 06:57 EOLS Mizuho analyst Vamil Divan raised the firm's price target on Evolus to $15 from $9 and keeps a Neutral rating on the shares following last week's agreements with partner Daewoong and the Q4 earnings report. The analyst see a "balanced risk/reward" while looking to see how Evolus competes following the resolution of various legal and financial overhangs. Show Related Items >>
--Entain upgraded to Overweight from Neutral at JPMorgan » 06:29 GMVHF JPMorgan analyst Daniel…
Houston we Have A problem-- that's my unknown stk with the gambling software that stops people from blowing themselves up.... This now has to bought!
GMVHF is the gummy of the day
& Don't forget Terranova's SCR
--Evolus price target raised to $15 from $9 at Mizuho 06:57 EOLS Mizuho analyst Vamil Divan raised the firm's price target on Evolus to $15 from $9 and keeps a Neutral rating on the shares following last week's agreements with partner Daewoong and the Q4 earnings report. The analyst see a "balanced risk/reward" while looking to see how Evolus competes following the resolution of various legal and financial overhangs. Show Related Items >>
--Entain upgraded to Overweight from Neutral at JPMorgan » 06:29 GMVHF JPMorgan analyst Daniel…
Houston we Have A problem-- that's my unknown stk with the gambling software that stops people from blowing themselves up.... This now has to bought!
GMVHF is the gummy of the day
& Don't forget Terranova's SCR